Dal Negro Roberto W, Turco Paola, Povero Massimiliano
National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology-CESFAR, 37124 Verona, Italy.
AdRes Health Economics and Outcomes Research, 10121 Turin, Italy.
Children (Basel). 2023 Nov 29;10(12):1876. doi: 10.3390/children10121876.
Bronchial asthma is characterized by variable airflow obstruction, airway inflammation, and bronchial hyperresponsiveness (BHR) to non-specific stimuli. The role of underlying airway inflammation and of related long-lasting BHR has been suboptimally investigated in teenagers with mild-to-moderate asthma, as has the corresponding economic impact over time. The aim of the present study was to calculate the cost of mild-to-moderate atopic asthma in teenagers arising from their degree of persisting BHR over a twelve-month period.
Patients aged 12-18 years with mild-to-moderate symptoms treated with fluticasone fumarate/vilanterol 92/22 mcg daily were retrospectively followed for 12 months. Usual spirometric parameters, BHR to methacholine (MCh), and resource consumption (visits, hospitalizations, systemic steroids and/or antibiotics courses, school days off) were assessed at recruitment (the index date) and after 6 and 12 months. Adherence to treatment was also calculated. The cost of asthma was calculated based on Italian tariffs and published papers. The trend over time in BHR and the association between response to MCh and total cost were investigated by using regression models adjusted for repeated measures.
106 teenagers (53 males, age 15.9 ± 1.6 years) were investigated. The annual cost of asthma proved significantly related to the BHR trend: every increment of a factor 10 in the response to MCh was associated with a saving of EUR 184.90 (95% CI -305.89 to -63.90). BHR was progressively optimized after 6 and 12 months in relation to the patients' compliance to treatment (≥70% of prescribed inhalation doses).
the usual spirometric parameters are largely insufficient to reflect the effects of underlying persistent inflammation in milder forms of asthma in teenagers. In terms of clinical governance, the periodic assessment of non-specific BHR is the appropriate procedure from this point of view. Non-specific BHR proves a reliable procedure for predicting and monitoring the economic impact of mild-to-moderate asthma in teenagers over time.
支气管哮喘的特征是气流受限可变、气道炎症以及对非特异性刺激的支气管高反应性(BHR)。在轻度至中度哮喘青少年中,潜在气道炎症及相关长期BHR的作用尚未得到充分研究,随着时间推移其相应的经济影响也未得到充分研究。本研究的目的是计算青少年轻度至中度特应性哮喘因持续12个月的BHR程度所产生的费用。
对年龄在12 - 18岁、每日使用92/22微克富马酸氟替卡松/维兰特罗治疗的轻度至中度症状患者进行为期12个月的回顾性随访。在招募时(索引日期)以及6个月和12个月后评估常规肺功能参数、对乙酰甲胆碱(MCh)的BHR以及资源消耗(就诊、住院、全身用类固醇和/或抗生素疗程、缺课天数)。还计算了治疗依从性。基于意大利收费标准和已发表论文计算哮喘费用。通过使用针对重复测量进行调整的回归模型,研究BHR随时间的变化趋势以及对MCh的反应与总成本之间的关联。
对106名青少年(53名男性,年龄15.9±1.6岁)进行了研究。哮喘的年度费用与BHR趋势显著相关:对MCh反应每增加10倍,费用节省184.90欧元(95%置信区间 - 305.89至 - 63.90)。与患者对治疗的依从性(≥规定吸入剂量的70%)相关,6个月和12个月后BHR逐渐得到优化。
常规肺功能参数在很大程度上不足以反映青少年较轻形式哮喘中潜在持续性炎症的影响。从临床管理角度来看,定期评估非特异性BHR是合适的程序。非特异性BHR被证明是预测和监测青少年轻度至中度哮喘随时间推移的经济影响的可靠程序。